RT Book, Section
A1 Granada, Juan F.
A1 Cheng, Yanping
A1 Scheller, Bruno
A2 Samady, Habib
A2 Fearon, William F.
A2 Yeung, Alan C.
A2 King III, Spencer B.
SR Print(0)
ID 1146598805
T1 Drug-Coated Balloon Technologies: Technical Features and Clinical Applications
T2 Interventional Cardiology, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071820363
LK accesscardiology.mhmedical.com/content.aspx?aid=1146598805
RD 2024/04/19
AB The  concept  of  delivering  antiproliferative  drugs  via  balloon  angioplasty  has  been  around  for  several  decades.  However,  the  specific  idea  of  developing  a  drug-coated  balloon  (DCB)  system  originated  from  the  seminal  work  of  professor  Ulrich  Speck  in  the  use  of  contrast  agents  as  carriers  of  antiproliferative  drugs.1  At  the  early  stages  of  his  research,  it  was  found  that  paclitaxel  solubility  was  significantly  increased  when  mixed  when  contrast  agents.  Experimental  data  showed  that  a  repeated  intracoronary  bolus  injection  of  a  taxane-iopromide  formulation  resulted  in  significant  reduction  of  neointimal  proliferation  in  the  porcine  model  of  restenosis.2,3  In  2001,  the  concept  of  mixing  iopromide  with  paclitaxel  in  a  form  of  a  balloon  coating  was  reduced  to  practice  and  validated  at  the  experimental  level.4  This  original  DCB  formulation  was  then  clinically  validated  in  small  randomized  controlled  studies  in  the  coronary  in-stent  restenosis5  and  de  novo  superficial  femoral  artery  stenosis  settings.6,7  Stimulated  by  these  early  clinical  results,  several  DCB  programs  were  started  following  a  similar  technologic  approach  of  using  hydrophilic  carriers  as  a  method  to  transport  paclitaxel  into  the  vessel  wall  after  balloon  dilatation.